AstraZeneca views $2B+ Fusion buyout as ‘starting point’ for better radiopharmaceuticals, combos

As the fifth ma­jor phar­ma play­er to stake a claim in ra­dio­phar­ma­ceu­ti­cals, As­traZeneca sees big po­ten­tial in im­prov­ing on cur­rent op­tions and ex­plor­ing com­bi­na­tion can­cer ther­a­pies through its $2 bil­lion ac­qui­si­tion of Fu­sion Phar­ma­ceu­ti­cals.

Fu­sion’s lead pro­gram, a po­ten­tial prostate can­cer ther­a­py, is ex­pect­ed to en­ter piv­otal tri­als in the next year or two, ac­cord­ing to Su­san Gal­braith, As­traZeneca’s head of on­col­o­gy R&D. But the deal was al­so done with a broad­er am­bi­tion to tap in­to what she sees as an “ex­cit­ing modal­i­ty op­por­tu­ni­ty for can­cer ther­a­py,” par­tic­u­lar­ly giv­en the man­u­fac­tur­ing ca­pa­bil­i­ty the new sub­sidiary brings. It’s al­so a bet on the spe­cif­ic type of ra­dioiso­topes that Fu­sion works with.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Healthcare is bullish on AI

It’s on­ly been about two years since health­care re­al­ly start­ed adopt­ing gen­er­a­tive AI. Now, it’s no longer just demos test­ing … Sign up to read

Read More »